{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:49:13Z","timestamp":1792482553072,"version":"4.5.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40620-020-00712-5","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:23:26Z","timestamp":1581985406000},"page":"985-994","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?"],"prefix":"10.1093","volume":"33","author":[{"given":"Megan Leila","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Anthony","family":"Perazella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"key":"712_CR1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","volume":"93","author":"DZI Cherney","year":"2018","unstructured":"Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ et al (2018) Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int 93:231\u2013244","journal-title":"Kidney Int"},{"key":"712_CR2","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.10180916","author":"S Petrykiv","year":"2017","unstructured":"Petrykiv S, David Sj\u00f6str\u00f6m C, Greasley PJ, Xu J, Persson F, Heerspink HJL (2017) Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function [internet]. Clin J Am Soc Nephrol. https:\/\/doi.org\/10.2215\/cjn.10180916","journal-title":"Clin J Am Soc Nephrol"},{"key":"712_CR3","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","volume":"138","author":"BL Neuen","year":"2018","unstructured":"Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW et al (2018) Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function: data from the CANVAS program. Circulation 138:1537\u20131550","journal-title":"Circulation"},{"key":"712_CR4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000498963","volume":"44","author":"C Chu","year":"2019","unstructured":"Chu C, Lu Y-P, Yin L, Hocher B (2019) The SGLT2 inhibitor empagliflozin might be a new approach for the prevention of acute kidney injury. Kidney Blood Press Res 44:149\u2013157","journal-title":"Kidney Blood Press Res"},{"key":"712_CR5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657","journal-title":"N Engl J Med"},{"key":"712_CR6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31\u201339","journal-title":"Lancet"},{"key":"712_CR7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13300-013-0030-2","volume":"4","author":"T Heise","year":"2013","unstructured":"Heise T, Seman L, Macha S, Jones P, Marquart A, Pinnetti S et al (2013) Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther 4:331\u2013345","journal-title":"Diabetes Ther"},{"key":"712_CR8","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Sabatine MS (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Reply. N Engl J Med 380:1881\u20131882","journal-title":"N Engl J Med"},{"key":"712_CR9","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"712_CR10","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008","journal-title":"N Engl J Med"},{"key":"712_CR11","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306","journal-title":"N Engl J Med"},{"key":"712_CR12","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/dom.13754","volume":"21","author":"RE Gilbert","year":"2019","unstructured":"Gilbert RE, Thorpe KE (2019) Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials. Diabetes Obes Metab 21:1996\u20132000","journal-title":"Diabetes Obes Metab"},{"key":"712_CR13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc17-1011","volume":"40","author":"GN Nadkarni","year":"2017","unstructured":"Nadkarni GN, Ferrandino R, Chang A, Surapaneni A, Chauhan K, Poojary P et al (2017) Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care 40:1479\u20131485","journal-title":"Diabetes Care"},{"key":"712_CR14","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L et al (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7:845\u2013854","journal-title":"Lancet Diabetes Endocrinol"},{"key":"712_CR15","unstructured":"FDA Center for Drug Evaluation and Research. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). In: U.S. Food and Drug Administration [Internet]. 14 Jun 2016 [cited 1 Aug 2019]. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin. Accessed 1 Aug 2019"},{"key":"712_CR16","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.numecd.2017.10.011","volume":"27","author":"A Perlman","year":"2017","unstructured":"Perlman A, Heyman SN, Matok I, Stokar J, Muszkat M, Szalat A (2017) Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis 27:1108\u20131113","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"712_CR17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","volume":"8","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Solini A (2012) SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8:495\u2013502","journal-title":"Nat Rev Endocrinol"},{"key":"712_CR18","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1056\/NEJMcibr1608564","volume":"375","author":"H-J Anders","year":"2016","unstructured":"Anders H-J, Davis JM, Thurau K (2016) Nephron protection in diabetic kidney disease. N Engl J Med 375:2096\u20132098","journal-title":"N Engl J Med"},{"key":"712_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1515920","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes [internet]. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa1515920","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"712_CR20","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.2215\/CJN.03250807","volume":"3","author":"GL Bakris","year":"2008","unstructured":"Bakris GL (2008) Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol 3(Suppl 1):S3\u201310","journal-title":"Clin J Am Soc Nephrol"},{"key":"712_CR21","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","volume":"20","author":"CCJ Dekkers","year":"2018","unstructured":"Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL (2018) Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab 20:1988\u20131993","journal-title":"Diabetes Obes Metab"},{"key":"712_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(17)30182-1","author":"DZI Cherney","year":"2017","unstructured":"Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M et al (2017) Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial [Internet]. Lancet Diabetes Endocrinol. https:\/\/doi.org\/10.1016\/s2213-8587(17)30182-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"712_CR23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13098-020-0516-9","volume":"12","author":"A Nakamura","year":"2020","unstructured":"Nakamura A, Miyoshi H, Kameda H, Yamashita K, Kurihara Y (2020) Impact of sodium-glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria. Diabetol Metab Syndr 12:4","journal-title":"Diabetol Metab Syndr"},{"key":"712_CR24","first-page":"814","volume":"4","author":"RE Gilbert","year":"2016","unstructured":"Gilbert RE (2016) SGLT2 inhibitors: \u03b2 blockers for the kidney? The lancet. Diabetes Endocrinol 4:814","journal-title":"Diabetes Endocrinol"},{"key":"712_CR25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2337\/diab.43.5.629","volume":"43","author":"A K\u00f6rner","year":"1994","unstructured":"K\u00f6rner A, Ekl\u00f6f AC, Celsi G, Aperia A (1994) Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes 43:629\u2013633","journal-title":"Diabetes"},{"key":"712_CR26","doi-asserted-by":"crossref","first-page":"e0158810","DOI":"10.1371\/journal.pone.0158810","volume":"11","author":"Y-K Chang","year":"2016","unstructured":"Chang Y-K, Choi H, Jeong JY, Na K-R, Lee KW, Lim BJ et al (2016) Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS ONE 11:e0158810","journal-title":"PLoS ONE"},{"key":"712_CR27","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00689.2014","author":"J Oneill","year":"2015","unstructured":"Oneill J, Fasching A, Pihl L, Patinha D, Franz\u00e9n S, Palm F (2015) Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats [Internet]. Am J Physiol Renal Physiol. https:\/\/doi.org\/10.1152\/ajprenal.00689.2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"712_CR28","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134:752\u2013772","journal-title":"Circulation"},{"key":"712_CR29","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR (2016) Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39:1115\u20131122","journal-title":"Diabetes Care"},{"key":"712_CR30","unstructured":"Wang XX, Levi J, Luo Y, Myakala K (2017) SGLT2 protein expression is increased in human diabetic nephropathy SGLT2 protein inhibition decreases renal lipid accumulation, inflammation. J Biol. https:\/\/www.jbc.org\/content\/292\/13\/5335.short. Accessed 25 Aug 2019"},{"key":"712_CR31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.gene.2019.05.009","volume":"707","author":"DI Mohamed","year":"2019","unstructured":"Mohamed DI, Khairy E, Saad SST, Habib EK, Hamouda MA (2019) Potential protective effects of Dapagliflozin in gentamicin induced nephrotoxicity rat model via modulation of apoptosis associated miRNAs. Gene 707:198\u2013204","journal-title":"Gene"},{"key":"712_CR32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC (2017) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60:215\u2013225","journal-title":"Diabetologia"},{"key":"712_CR33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00210-018-1564-7","volume":"392","author":"AM Abdelrahman","year":"2019","unstructured":"Abdelrahman AM, Al Suleimani Y, Shalaby A, Ashique M, Manoj P, Nemmar A et al (2019) Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice. Naunyn Schmiedebergs Arch Pharmacol 392:45\u201353","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"712_CR34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ejim.2012.06.003","volume":"23","author":"CT Postma","year":"2012","unstructured":"Postma CT, Klappe EM, Dekker HM, Thien T (2012) The prevalence of renal artery stenosis among patients with diabetes mellitus. Eur J Intern Med 23:639\u2013642","journal-title":"Eur J Intern Med"},{"key":"712_CR35","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJM199503093321006","volume":"332","author":"M Brezis","year":"1995","unstructured":"Brezis M, Rosen S (1995) Hypoxia of the renal medulla\u2014its implications for disease. N Engl J Med 332:647\u2013655","journal-title":"N Engl J Med"},{"key":"712_CR36","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/ki.1984.185","volume":"26","author":"M Brezis","year":"1984","unstructured":"Brezis M, Rosen S, Silva P, Epstein FH (1984) Renal ischemia: a new perspective. Kidney Int 26:375\u2013383","journal-title":"Kidney Int"},{"key":"712_CR37","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00125-003-1155-z","volume":"46","author":"F Palm","year":"2003","unstructured":"Palm F, Cederberg J, Hansell P, Liss P, Carlsson P-O (2003) Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia 46:1153\u20131160","journal-title":"Diabetologia"},{"key":"712_CR38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/jmri.10224","volume":"17","author":"M Ries","year":"2003","unstructured":"Ries M, Basseau F, Tyndal B, Jones R, Demini\u00e8re C, Catargi B et al (2003) Renal diffusion and BOLD MRI in experimental diabetic nephropathy. J Magn Reson Imaging 17:104\u2013113","journal-title":"J Magn Reson Imaging"},{"key":"712_CR39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.ki.5002567","volume":"73","author":"C Rosenberger","year":"2008","unstructured":"Rosenberger C, Khamaisi M, Abassi Z, Shilo V, Weksler-Zangen S, Goldfarb M et al (2008) Adaptation to hypoxia in the diabetic rat kidney. Kidney Int 73:34\u201342","journal-title":"Kidney Int"},{"key":"712_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.107","author":"CY Hsu","year":"2008","unstructured":"Hsu CY, Ordo\u00f1ez JD, Chertow GM, Fan D, McCulloch CE, Go AS (2008) The risk of acute renal failure in patients with chronic kidney disease [Internet]. Kidney Int. https:\/\/doi.org\/10.1038\/ki.2008.107","journal-title":"Kidney Int"},{"key":"712_CR41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40264-017-0602-6","volume":"41","author":"A Szalat","year":"2018","unstructured":"Szalat A, Perlman A, Muszkat M, Khamaisi M, Abassi Z, Heyman SN (2018) Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf 41:239\u2013252","journal-title":"Drug Saf"},{"key":"712_CR42","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15:853\u2013862","journal-title":"Diabetes Obes Metab"},{"key":"712_CR43","doi-asserted-by":"crossref","first-page":"176","DOI":"10.14740\/jocmr2849w","volume":"9","author":"SN Heyman","year":"2017","unstructured":"Heyman SN, Khamaisi M, Rosenberger C, Szalat A, Abassi Z (2017) Increased hematocrit during sodium-glucose cotransporter-2 inhibitor therapy. J Clin Med Res 9:176\u2013177","journal-title":"J Clin Med Res"},{"issue":"Suppl 1","key":"712_CR44","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1111\/j.1556-4029.2012.02274.x","volume":"58","author":"C Zhou","year":"2013","unstructured":"Zhou C, Yool AJ, Nolan J, Byard RW (2013) Armanni\u2013Ebstein lesions: a need for clarification. J Forensic Sci 58(Suppl 1):S94\u2013S98","journal-title":"J Forensic Sci"},{"key":"712_CR45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0379-0738(94)90087-6","volume":"67","author":"KF Kock","year":"1994","unstructured":"Kock KF, Vestergaard V (1994) Armanni-Ebstein lesions of the kidney: diagnostic of death in diabetic coma? Forensic Sci Int 67:169\u2013174","journal-title":"Forensic Sci Int"},{"key":"712_CR46","first-page":"1035","volume":"33","author":"S Ritchie","year":"1957","unstructured":"Ritchie S, Waugh D (1957) The pathology of Armanni\u2013Ebstein diabetic nephropathy. Am J Pathol 33:1035\u20131057","journal-title":"Am J Pathol"},{"key":"712_CR47","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrneph.2016.159","volume":"12","author":"K Hahn","year":"2016","unstructured":"Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ (2016) Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol 12:711\u2013712","journal-title":"Nat Rev Nephrol"},{"key":"712_CR48","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00747.x","author":"H Kitamura","year":"1998","unstructured":"Kitamura H, Yamauchi A, Sugiura T, Matsuoka Y, Horio M, Tohyama M et al (1998) Inhibition of myo-inositol transport causes acute renal failure with selective medullary injury in the rat [Internet]. Kidney Int. https:\/\/doi.org\/10.1046\/j.1523-1755.1998.00747.x","journal-title":"Kidney Int"},{"key":"712_CR49","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1164\/rccm.201311-2097OC","volume":"189","author":"A Linder","year":"2014","unstructured":"Linder A, Fjell C, Levin A, Walley KR, Russell JA, Boyd JH (2014) Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill. Am J Respir Crit Care Med 189:1075\u20131081","journal-title":"Am J Respir Crit Care Med"},{"key":"712_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy122","author":"B Satirapoj","year":"2019","unstructured":"Satirapoj B, Korkiatpitak P, Supasyndh O (2019) Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial [Internet]. Clin Kidney J. https:\/\/doi.org\/10.1093\/ckj\/sfy122","journal-title":"Clin Kidney J"},{"key":"712_CR51","first-page":"513","volume":"20","author":"A Perlman","year":"2018","unstructured":"Perlman A, Heyman SN, Stokar J, Darmon D, Muszkat M, Szalat A (2018) Clinical spectrum and mechanism of acute kidney injury in patients with diabetes mellitus on SGLT-2 inhibitors. Isr Med Assoc J 20:513\u2013516","journal-title":"Isr Med Assoc J"},{"key":"712_CR52","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.2337\/dc16-2200","volume":"40","author":"SN Heyman","year":"2017","unstructured":"Heyman SN, Khamaisi M, Rosen S, Rosenberger C, Abassi Z (2017) Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media. Diabetes Care 40:e40\u2013e41","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"712_CR53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.13611","volume":"21","author":"D Fitchett","year":"2019","unstructured":"Fitchett D (2019) A safety update on sodium glucose co-transporter 2 inhibitors. Diabetes Obes Metab 21(Suppl 2):34\u201342","journal-title":"Diabetes Obes Metab"},{"key":"712_CR54","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00007","author":"D Vasilakou","year":"2013","unstructured":"Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E et al (2013) Sodium\u2013glucose cotransporter 2 inhibitors for type 2 diabetes [internet]. Ann Internal Med. https:\/\/doi.org\/10.7326\/0003-4819-159-4-201308200-00007","journal-title":"Ann Internal Med"},{"key":"712_CR55","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/dom.13532","volume":"21","author":"A Cahn","year":"2019","unstructured":"Cahn A, Melzer-Cohen C, Pollack R, Chodick G, Shalev V (2019) Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis. Diabetes Obes Metab 21:340\u2013348","journal-title":"Diabetes Obes Metab"},{"key":"712_CR56","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199604113341502","author":"G Maschio","year":"1996","unstructured":"Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M et al (1996) Effect of the angiotensin-converting\u2013enzyme inhibitor benazepril on the progression of chronic renal insufficiency [Internet]. N Engl J Med. https:\/\/doi.org\/10.1056\/nejm199604113341502","journal-title":"N Engl J Med"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00712-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-020-00712-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00712-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:31Z","timestamp":1777564591000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/33\/5\/985\/8328464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["712"],"URL":"https:\/\/doi.org\/10.1007\/s40620-020-00712-5","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,18]]},"assertion":[{"value":"9 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Neither author (MAP or MLB) have any conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"There is no need for informed consent as there is no patient research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}